# Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

> **NCT01733147** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 60 (actual)

## Conditions studied

- Barrett's Esophagus
- Obesity

## Interventions

- **DRUG:** Omega-3 polyunsaturated fatty acids
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01733147
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733147, "Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01733147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*